Skip to content

Study · Randomized controlled trial · 2012

5 results

The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.

Damber JE, Tammela TL, Iversen P, Abrahamsson PA, Boccon-Gibod L, Olesen TK, van der Meulen E, Persson BE

Urology1 Jul 2012Cited by 21 (Europe PMC)

PMID22748873 (opens in a new tab)DOI10.1016/j.urology.2012.01.092 (opens in a new tab)PepBankPUB-22748873
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In prostate cancer patients, castrate testosterone occurred faster with degarelix than leuprolide with optional antiandrogens, irrespective of baseline testosterone.

    In plain wordsIn prostate cancer patients, testosterone suppression occurred faster with degarelix than leuprolide with optional antiandrogens, regardless of starting testosterone.

    Peptide
    Degarelix
    Outcome
    DecreaseTime to castrate testosterone
    Study

    n: not reported in source

    Comparator
    Leuprolide with optional antiandrogens
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    240 mg initial, then 80 mg monthly · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    However, castrate testosterone levels and PSA suppression occurred more rapidly with degarelix irrespective of baseline testosterone.
    3 context sentences
    Summary · context
    In CS21, patients with histologically confirmed prostate cancer (all stages) were randomized to degarelix 240 mg for 1 month followed by monthly maintenance doses of 80 or 160 mg, or leuprolide 7.5 mg/month.
    Summary · context
    Patients receiving leuprolide could receive antiandrogens for flare protection.
    Summary · context
    Data are presented for the groups receiving degarelix 240/80 mg (the approved dose) and leuprolide 7.5 mg.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In prostate cancer patients, PSA suppression occurred faster with degarelix than leuprolide with optional antiandrogens, irrespective of baseline testosterone.

    In plain wordsIn prostate cancer patients, PSA suppression occurred faster with degarelix than leuprolide with optional antiandrogens, regardless of starting testosterone.

    Peptide
    Degarelix
    Outcome
    DecreaseTime to PSA suppression
    Study

    n: not reported in source

    Comparator
    Leuprolide with optional antiandrogens
    Outcome group
    Tumor growth · Cancer
    Studied dose
    240 mg initial, then 80 mg monthly · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    However, castrate testosterone levels and PSA suppression occurred more rapidly with degarelix irrespective of baseline testosterone.
    3 context sentences
    Summary · context
    In CS21, patients with histologically confirmed prostate cancer (all stages) were randomized to degarelix 240 mg for 1 month followed by monthly maintenance doses of 80 or 160 mg, or leuprolide 7.5 mg/month.
    Summary · context
    Patients receiving leuprolide could receive antiandrogens for flare protection.
    Summary · context
    Data are presented for the groups receiving degarelix 240/80 mg (the approved dose) and leuprolide 7.5 mg.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In prostate cancer patients with high baseline testosterone, PSA suppression tended to be faster with degarelix than leuprolide with optional antiandrogens.

    In plain wordsIn prostate cancer patients with high starting testosterone, PSA suppression tended to be faster with degarelix than leuprolide with optional antiandrogens.

    Peptide
    Degarelix
    Outcome
    DecreasePSA suppression in high baseline testosterone subgroup
    Study

    n: not reported in source

    Comparator
    Leuprolide with optional antiandrogens
    Outcome group
    Tumor growth · Cancer
    Studied dose
    240 mg initial, then 80 mg monthly · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no overall correlation between baseline testosterone and initial PSA decrease in either treatment group, although PSA suppression tended to be slowest with leuprolide and fastest with degarelix in the high baseline testosterone subgroup.
    3 context sentences
    Summary · context
    In CS21, patients with histologically confirmed prostate cancer (all stages) were randomized to degarelix 240 mg for 1 month followed by monthly maintenance doses of 80 or 160 mg, or leuprolide 7.5 mg/month.
    Summary · context
    Patients receiving leuprolide could receive antiandrogens for flare protection.
    Summary · context
    Data are presented for the groups receiving degarelix 240/80 mg (the approved dose) and leuprolide 7.5 mg.
  4. 04HumanObservational studyEfficacy outcome

    In prostate cancer patients receiving degarelix, higher baseline testosterone delayed castration, as it did with leuprolide.

    In plain wordsIn prostate cancer patients receiving degarelix, higher starting testosterone delayed testosterone suppression, as it did with leuprolide.

    Peptide
    Degarelix
    Outcome
    IncreaseTime to castration by baseline testosterone
    Study

    n: not reported in source

    Comparator
    Lower baseline testosterone
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    240 mg initial, then 80 mg monthly · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Higher baseline testosterone delayed castration with both treatments.
    3 context sentences
    Summary · context
    In CS21, patients with histologically confirmed prostate cancer (all stages) were randomized to degarelix 240 mg for 1 month followed by monthly maintenance doses of 80 or 160 mg, or leuprolide 7.5 mg/month.
    Summary · context
    Patients receiving leuprolide could receive antiandrogens for flare protection.
    Summary · context
    Data are presented for the groups receiving degarelix 240/80 mg (the approved dose) and leuprolide 7.5 mg.
  5. 05HumanObservational studyEfficacy outcome

    In prostate cancer patients receiving degarelix, baseline testosterone had no overall correlation with initial PSA decrease.

    In plain wordsIn prostate cancer patients receiving degarelix, starting testosterone had no overall link to the initial PSA decrease.

    Peptide
    Degarelix
    Outcome
    No significant changeCorrelation of baseline testosterone with initial PSA decrease
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    240 mg initial, then 80 mg monthly · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no overall correlation between baseline testosterone and initial PSA decrease in either treatment group, although PSA suppression tended to be slowest with leuprolide and fastest with degarelix in the high baseline testosterone subgroup.
    3 context sentences
    Summary · context
    In CS21, patients with histologically confirmed prostate cancer (all stages) were randomized to degarelix 240 mg for 1 month followed by monthly maintenance doses of 80 or 160 mg, or leuprolide 7.5 mg/month.
    Summary · context
    Patients receiving leuprolide could receive antiandrogens for flare protection.
    Summary · context
    Data are presented for the groups receiving degarelix 240/80 mg (the approved dose) and leuprolide 7.5 mg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.